Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
NCT ID: NCT06844864
Last Updated: 2025-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
20 participants
OBSERVATIONAL
2025-03-01
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
NCT05986162
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
NCT03864185
A Registered Cohort Study of Immune-Mediated Neuropathies
NCT04292834
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
NCT02725476
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate with Ultimate Dosing
NCT04356781
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent
* Active IgG4-RD based on the IgG4-related disease activity index
* Fulfillment of the 2019 ACR/EULAR Classification Criteria for IgG4RD
Healthy Controls:
* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent
Exclusion Criteria
* Subjects \< 18 years of age
* Pregnant women
* Comorbidities (other ongoing active autoimmune diseases, ongoing cancer, ongoing infections)
* Ongoing immunosuppressive therapy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS San Raffaele
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emanuel Della Torre
Principal Investigator, Assistant Professor of Internal Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedale San Raffaele
Milan, MI, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022FH5R92
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2022FH5R92
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.